Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Med Arch. 2013; 67(4): 241-244


Serum Level of Tumor Marker Carbohydrate Antigen-CA125 in Heart Failure

Azra Durak-Nalbantic, Nerma Resic, Mehmed Kulic, Ehlimana Pecar, Faris Zvizdic, Alen Dzubur, Mirza Dilic, Refet Gojak, Sekib Sokolovic, Enisa Hodzic, Snezana Brdjanovic.




Abstract

Objective: To assess serum levels of tumor marker carbohydrate antigen 125 (CA125) in patients with heart failure (HF) and to investigate possible correlation with echocardiographic parameters and level of brain natriuretic peptide (BNP). Patients and methods: We included 76 patients with different cardiac symptoms hospitalized at Clinic for heart disease and rheumatism. Control group (n=26) was consisted of patients without signs and symptoms of HF, normal left ventricle ejection fraction (LVEF) and normal BNP level. Patients with diagnosis of HF (n=50) were subdivided into 2 group depending on signs and symptoms of fluid overload: compensated (compHF, n=10) and decompensated group (decompHF, n=40). Serum CA125 and BNP were measured on admission and all patient underwent ECG recording and trans thoracic echocardiographic examination. Results: The median CA125 level in HF group was significantly higher compared to control group (71.05 [30.70-141.47]U/ml vs 10.75 [8.05- 14.32]U/ml, p

Key words: heart failure; tumor marker CA125; volume overload






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.